Adrenal Cancer (Adrenocortical Carcinoma)
Rare but aggressive malignancy of the adrenal cortex driven by cortisol and androgen hypersecretion requiring specialized nutritional and hormonal management
Overview
Adrenocortical carcinoma (ACC) is a rare malignancy (~1–2 per million/year) arising from the adrenal cortex. Approximately 60% are hormonally functional, secreting excess cortisol (Cushing syndrome), androgens, aldosterone, or mixed hormones. Five-year survival is ~35–60% for localized disease and <15% for metastatic ACC. Standard treatment is surgical resection (adrenalectomy) for localized disease; mitotane (adrenolytic agent) is the cornerstone of systemic therapy — used adjuvantly and for advanced disease. Chemotherapy (EDP-M: etoposide, doxorubicin, cisplatin + mitotane) is used for advanced ACC. Immunotherapy (pembrolizumab, nivolumab) shows modest activity in ACC. 2025–2026 advances: ADIUVO-2 trial (results pending 2025) — adjuvant mitotane + EDP-M chemotherapy vs mitotane alone for high-risk resected ACC; ADIUVO trial (2023) showed adjuvant mitotane alone did NOT improve RFS vs observation in low-risk resected ACC — changing adjuvant practice; pembrolizumab for advanced ACC (KEYNOTE-B84: 14% ORR — modest but durable responses in a disease with few options); nivolumab for advanced ACC (Phase II: 11% ORR); linsitinib (IGF-1R inhibitor) — Phase II for advanced ACC (IGF-1R overexpressed in ~90% of ACC); CDK4/6 inhibitors (palbociclib, ribociclib) for CDK4-amplified ACC (~30% of ACC); osilodrostat (Isturisa — 11-beta hydroxylase inhibitor, FDA approved 2020) for Cushing syndrome in ACC — more potent cortisol control than ketoconazole/metyrapone; levoketoconazole (Recorlev — FDA approved 2021) for Cushing syndrome in ACC; mitotane therapeutic drug monitoring (TDM) — target blood levels 14–20 mg/L; levels <14 mg/L are ineffective; levels >20 mg/L cause severe neurotoxicity; TDM is now standard of care; comprehensive molecular profiling (TP53, CTNNB1, ZNRF3, DAXX, TERT, CDK4, MDM2) recommended for all advanced ACC to guide clinical trial eligibility. Nutritional rationale: cortisol excess causes muscle wasting, hyperglycemia, osteoporosis, and immune suppression — all requiring targeted nutritional intervention; mitotane causes severe GI toxicity and adrenal insufficiency requiring glucocorticoid replacement and fat-soluble vitamin support.
Evidence highlight: Mitotane is the only FDA-approved drug specifically for ACC. ADIUVO trial (2023): adjuvant mitotane alone did NOT improve RFS vs observation in low-risk resected ACC — changing adjuvant practice. ADIUVO-2 evaluating adjuvant mitotane + EDP-M for high-risk disease (results pending 2025). KEYNOTE-B84: pembrolizumab 14% ORR in advanced ACC. Osilodrostat FDA approved 2020 for Cushing syndrome — LINC3 trial: 86% cortisol normalization. Levoketoconazole FDA approved 2021 for Cushing syndrome — SONICS trial: 30% cortisol normalization. Mitotane TDM (target 14–20 mg/L) is now standard of care. High-fat meals increase mitotane bioavailability by 2–3x (Hermsen et al., 2011). Vitamin D deficiency is associated with worse ACC prognosis. Cortisol-driven osteoporosis requires aggressive calcium/D3/K2 supplementation — evidence from Cushing syndrome literature.
Core Nutrition Principles
- 1Cortisol excess (Cushing syndrome) causes muscle catabolism — high protein intake (1.5–2g/kg/day) is essential to preserve lean mass
- 2Hypercortisolism drives hyperglycemia and insulin resistance — low-glycemic, high-fiber diet is critical
- 3Mitotane causes severe nausea, vomiting, and fat malabsorption — small frequent meals and MCT oil improve tolerance
- 4Mitotane induces adrenal insufficiency — glucocorticoid replacement (hydrocortisone) is mandatory; nutritional support for adrenal function
- 5Cortisol-driven osteoporosis requires aggressive calcium, vitamin D3, and vitamin K2 supplementation
- 6Mitotane is highly lipophilic — high-fat meals increase mitotane absorption and blood levels; consistent fat intake with each dose is recommended
- 7Selenium and antioxidants support adrenal tissue and reduce oxidative stress from cortisol excess
- 8Potassium-rich foods counteract aldosterone-driven hypokalemia in aldosterone-secreting tumors
Priority Foods
- High-quality protein (chicken, turkey, eggs, Greek yogurt) — 1.5–2g/kg/day; counteract cortisol-driven muscle catabolism; support immune function
- Low-glycemic vegetables (broccoli, spinach, kale, cauliflower) — stabilize blood sugar; anti-inflammatory; cruciferous compounds support detoxification
- Avocado and olive oil — healthy monounsaturated fats; increase mitotane absorption when taken with medication; anti-inflammatory
- Potassium-rich foods (bananas, sweet potatoes, leafy greens) — counteract aldosterone-driven hypokalemia; support electrolyte balance
- Fatty fish (salmon, sardines, mackerel) — omega-3 EPA/DHA; reduce cortisol-driven inflammation; support cardiovascular health
- Bone broth — collagen, glycine, proline; support bone density and connective tissue affected by hypercortisolism
- Fermented foods (kefir, yogurt, kimchi) — restore gut microbiome disrupted by cortisol and chemotherapy
- Brazil nuts (2/day) — selenium; adrenal antioxidant support; 200mcg selenium from food sources
- Whole grains (oats, quinoa, brown rice) — fiber; stabilize blood sugar; B vitamins for adrenal function
- Ginger and turmeric — anti-nausea (critical during mitotane therapy); anti-inflammatory; NF-kB inhibition
Core Supplements
- Vitamin D3 — 5,000–10,000 IU daily with K2 (200mcg MK-7); cortisol-driven osteoporosis prevention; immune support; check 25-OH-D levels; target 60–80 ng/mL
- Calcium citrate — 1,200–1,500mg daily in divided doses; osteoporosis prevention from hypercortisolism; citrate form preferred for absorption
- Vitamin K2 (MK-7) — 200mcg daily; directs calcium to bone not arteries; essential with D3 in hypercortisolism-driven bone loss
- Magnesium glycinate — 400–600mg daily; cortisol-driven magnesium depletion; muscle function; sleep; blood sugar regulation
- Omega-3 EPA/DHA — 3–4g daily; reduce cortisol-driven inflammation; cardiovascular protection; anti-cachexia
- Selenium — 200mcg daily as selenomethionine; adrenal antioxidant; immune support; may reduce chemotherapy toxicity
- Vitamin C — 1,000–2,000mg daily; adrenal gland requires highest vitamin C concentration of any tissue; antioxidant; immune support
- B-complex (activated) — B5 (pantothenic acid 500mg), B6 (P5P 50mg), B12 (methylcobalamin 1,000mcg); adrenal hormone synthesis; energy metabolism
- Probiotics (50 billion CFU multi-strain) — restore gut microbiome; reduce mitotane GI toxicity; Lactobacillus rhamnosus GG + Bifidobacterium longum
- Melatonin — 10–20mg at bedtime; anti-tumor properties; improves sleep disrupted by cortisol excess; antioxidant; discuss with oncologist
- MCT oil — 1–2 tablespoons daily; improves fat absorption with mitotane; calorie-dense for weight maintenance; medium-chain fats bypass lymphatic absorption
- Glutamine — 10–20g daily; gut mucosal integrity during chemotherapy; reduce GI toxicity; muscle preservation
Treatment Protocols
- Adrenalectomy — surgical resection is the primary curative treatment for localized ACC; laparoscopic for small tumors; open for large or invasive tumors
- Mitotane (Lysodren) — adrenolytic agent; cornerstone of adjuvant and advanced ACC treatment; target blood levels 14–20 mg/L; take with high-fat meals to maximize absorption; causes adrenal insufficiency requiring glucocorticoid replacement
- Glucocorticoid replacement — hydrocortisone 15–25mg/day in divided doses (mandatory during mitotane therapy); stress dosing during illness/surgery
- EDP-M chemotherapy — etoposide + doxorubicin + cisplatin + mitotane; standard for advanced/metastatic ACC; significant toxicity
- Pembrolizumab or nivolumab — immunotherapy showing modest activity in ACC; PD-L1 expression guides use; ongoing trials
- IGF-1R inhibitors (linsitinib) — investigational; IGF-1R overexpressed in ACC; early clinical trials showing promise
- CDK4/6 inhibitors — investigational for ACC; CDK4 amplification in subset of ACC tumors
- Radiation therapy — for bone metastases (palliative); stereotactic body radiation (SBRT) for oligometastatic disease
- Cushing syndrome management — ketoconazole, metyrapone, or osilodrostat to control cortisol excess pre-operatively or in unresectable disease
- Bone density monitoring — DEXA scan at baseline and annually; bisphosphonates (alendronate) or denosumab for osteoporosis
- Blood sugar monitoring — cortisol excess causes steroid diabetes; low-glycemic diet + metformin if needed
- ADIUVO trial (2023) — adjuvant mitotane alone did NOT improve RFS vs observation in low-risk resected ACC; changes adjuvant practice — observation now preferred for low-risk resected ACC; ADIUVO-2 evaluating adjuvant mitotane + EDP-M for high-risk disease (results pending 2025)
- Pembrolizumab for advanced ACC (KEYNOTE-B84) — 14% ORR in advanced ACC; modest but durable responses; option after EDP-M failure; PD-L1 expression does not predict response in ACC
- Osilodrostat (Isturisa) — 11-beta hydroxylase inhibitor; FDA approved 2020 for Cushing syndrome including ACC; more potent cortisol control than ketoconazole or metyrapone; oral twice daily; LINC3 trial: 86% cortisol normalization
- Levoketoconazole (Recorlev) — FDA approved 2021 for Cushing syndrome including ACC; ketoconazole enantiomer with improved safety profile; oral twice daily; SONICS trial: 30% cortisol normalization
- Mitotane therapeutic drug monitoring (TDM) — target blood levels 14–20 mg/L; levels <14 mg/L are ineffective; levels >20 mg/L cause severe neurotoxicity (ataxia, confusion); TDM every 4–6 weeks is now standard of care; takes 3–6 months to reach therapeutic levels
- Linsitinib (IGF-1R inhibitor) — Phase II for advanced ACC; IGF-1R overexpressed in ~90% of ACC; investigational; combination with mitotane being evaluated
- CDK4/6 inhibitors (palbociclib, ribociclib) — for CDK4-amplified ACC (~30% of ACC); CDK4 amplification is the most common targetable alteration in ACC; investigational; Phase II trials ongoing
- Comprehensive molecular profiling — TP53, CTNNB1, ZNRF3, DAXX, TERT, CDK4, MDM2; recommended for all advanced ACC; CDK4 amplification and TP53 mutation are most common actionable alterations; guides clinical trial eligibility
- Endocrinology consultation — essential for hormone replacement management and Cushing syndrome control
Foods & Substances to Avoid
- High-glycemic foods (white bread, sugary drinks, candy) — cortisol excess already drives hyperglycemia and insulin resistance; exacerbates steroid diabetes
- Alcohol — hepatotoxic; interacts with mitotane metabolism; impairs adrenal function; worsens cortisol dysregulation
- Grapefruit and grapefruit juice — inhibits CYP3A4; significantly alters mitotane and chemotherapy drug levels
- St. John's Wort — potent CYP3A4 inducer; reduces mitotane and chemotherapy efficacy
- High-sodium foods — aldosterone-secreting ACC causes hypertension and hypokalemia; sodium restriction critical
- Licorice root supplements — mimics aldosterone; worsens hypertension and hypokalemia in aldosterone-secreting ACC
- Raw or undercooked foods during chemotherapy — infection risk during immunosuppression
- Excess caffeine — worsens cortisol-driven anxiety, insomnia, and cardiovascular stress
- Processed meats and refined oils — pro-inflammatory; worsen cortisol-driven inflammation and cardiovascular risk
Get your personalized protocol
Take the full assessment to receive a protocol tailored to your specific symptoms and goals.
Start AssessmentKey Nutrients
Drug & Supplement Interactions
Some nutrients in this protocol may interact with medications. Always inform your prescriber of all supplements you take.
- •Warfarin (Coumadin) — vitamin K directly antagonizes warfarin; any change in intake requires INR monitoring
- •Other anticoagulants (rivaroxaban, apixaban) — consult prescriber before supplementing
- •Antibiotics — broad-spectrum antibiotics reduce gut bacteria that produce vitamin K2
- •Warfarin (Coumadin) — directly antagonizes anticoagulant effect; requires INR monitoring
- •Other anticoagulants — consult prescriber; even small changes in K2 intake affect INR
- •Retinoids (isotretinoin, tretinoin) — additive toxicity risk; do not combine
- •Warfarin — high-dose vitamin A may increase anticoagulant effect
- •Orlistat — reduces fat-soluble vitamin absorption including vitamin A
- •Cholestyramine — reduces vitamin A absorption
- •Levodopa — B6 reduces drug effectiveness; avoid unless combined with carbidopa
- •Phenytoin and phenobarbital — B6 may reduce drug levels
- •Statins — combination increases risk of myopathy; use with caution
- •Diabetes medications — high-dose niacin may impair glucose control
- •Blood pressure medications — additive vasodilatory effect
- •Thiazide diuretics — combined with high-dose vitamin D may cause hypercalcemia
- •Digoxin — hypercalcemia from excess vitamin D increases digoxin toxicity risk
- •Corticosteroids — long-term use depletes vitamin D; supplementation is recommended
- •Orlistat (weight loss drug) — reduces vitamin D absorption by up to 30%
- •Cholestyramine — reduces vitamin D absorption; separate by 4+ hours
- •Phenobarbital and phenytoin — accelerate vitamin D metabolism; may require higher doses
- •Blood thinners (warfarin, aspirin) — additive antiplatelet effect at doses >400 IU/day
- •Chemotherapy and radiation — high-dose vitamin E may reduce treatment effectiveness; consult oncologist
- •Statins — may reduce statin effectiveness at very high doses
- •Cyclosporine — may reduce drug levels
- •Niacin — high-dose combination may reduce HDL-raising effect of niacin
- •Warfarin — high doses (>1g/day) may reduce anticoagulant effect
- •Chemotherapy — high-dose IV vitamin C may interact with certain agents; consult oncologist
- •Iron supplements — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)
- •Statins — very high doses may reduce statin effectiveness
- •Aluminum antacids — vitamin C increases aluminum absorption; avoid combination
- •Metformin — long-term use depletes B12; supplementation is recommended
- •PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
- •Chloramphenicol — may reduce B12 effectiveness
- •Thyroid medications (levothyroxine) — calcium reduces absorption; separate by 4+ hours
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces antibiotic absorption; separate by 2+ hours
- •Bisphosphonates — reduces absorption; separate by 2+ hours
- •Iron supplements — compete for absorption; separate by 2+ hours
- •Digoxin — high calcium may increase risk of digoxin toxicity
- •Thiazide diuretics — may cause hypercalcemia when combined with calcium supplements
- •Antibiotics (tetracyclines, fluoroquinolones) — magnesium reduces absorption; separate by 2+ hours
- •Bisphosphonates (alendronate) — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Diuretics — thiazide diuretics increase magnesium excretion; loop diuretics may deplete magnesium
- •Digoxin — magnesium deficiency increases digoxin toxicity risk; supplementation may be protective
- •Muscle relaxants — additive effect; may increase sedation
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
- •Bisphosphonates — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Antibiotics — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Blood thinners (warfarin, clopidogrel, aspirin) — additive antiplatelet effect; monitor INR at doses >2g/day
- •Blood pressure medications — additive hypotensive effect at high doses (>3g/day)
- •Cyclosporine — may reduce drug levels; monitor in transplant patients
- •Chemotherapy (cisplatin) — may reduce drug effectiveness; consult oncologist
- •Anticoagulants — high doses may have mild antiplatelet effect
- •Statins — may interact with statin metabolism at high doses
- •Diabetes medications — MCTs may affect blood glucose; monitor
- •Lactulose (for hepatic encephalopathy) — glutamine may worsen ammonia levels in liver disease
- •Anticonvulsants — glutamine may lower seizure threshold in some individuals
- •Chemotherapy — may interfere with some agents; consult oncologist
This list covers common interactions and is not exhaustive. Consult a pharmacist or physician before combining supplements with prescription medications.
Related Conditions
This protocol is for informational purposes only. Consult a qualified healthcare provider before making dietary or supplement changes.